Market Update (NYSE:MRK): Allergan Enters Into Licensing Agreement with Merck to Obtain Exclusive Worldwide Rights to CGRP Migraine Development Program

[PR Newswire] – Under the terms of the agreement, Allergan will acquire these rights for an upfront payment of $250 million, $125 million of which is payable upon HSR clearance and $125 million . . . → Read More: Market Update (NYSE:MRK): Allergan Enters Into Licensing Agreement with Merck to Obtain Exclusive Worldwide Rights to CGRP Migraine Development Program Similar Articles: Company Update (NYSE:MRK): Merck to Hold Second-Quarter 2015 Sales and Earnings Conference Call on July 28 Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly’s investigational medicine for prevention of migraine met primary endpoint in a Phase 2b study Company Update: Merck & Co Inc (NYSE:MRK) – Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress